Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C13H16FN3O2.H2O |
| Molecular Weight | 283.2987 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.CC(=O)N1CCN(CC1)NC(=O)C2=CC=C(F)C=C2
InChI
InChIKey=YCRCWHFFTTVANS-UHFFFAOYSA-N
InChI=1S/C13H16FN3O2.H2O/c1-10(18)16-6-8-17(9-7-16)15-13(19)11-2-4-12(14)5-3-11;/h2-5H,6-9H2,1H3,(H,15,19);1H2
| Molecular Formula | H2O |
| Molecular Weight | 18.0153 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C13H16FN3O2 |
| Molecular Weight | 265.2834 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/11172755
http://adisinsight.springer.com/drugs/800008887
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/11172755
http://adisinsight.springer.com/drugs/800008887
FK-960 [N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate], a novel putative anti-dementia drug of piperazine derivative, ameliorates memory deficits in a variety of animal models of dementia in rats and monkeys, and also augments long-term potentiation (LTP) in the mossy fiber-CA3 pathway in guinea-pig hippocampal slices. FK-960 acts as Serotonin modulator. FK-960 had been in phase II clinical trials by Fujisawa Pharmaceutical (now Astellas) for the treatment of Alzheimer's disease (AD). However this study was suspended. In 2003 Phase-II for Alzheimer's disease in USA was discontinued and in Jul 2004 - Phase-II for Cognition disorders in Europe.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14680454 | https://www.ncbi.nlm.nih.gov/pubmed/12515883
Curator's Comment: After oral administration to rhesus monkeys, FK960 is distributed to the entire brain.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: GO:0035249 |
|||
Target ID: GO:0042428 |
|||
Target ID: GO:0070253 |
|||
Target ID: Q07731|||Q9QXJ8 Gene ID: 25453.0 Gene Symbol: Gdnf Target Organism: Rattus norvegicus (Rat) |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
Sample Use Guides
Rhesus macaques: FK960 was intramuscularly administered at doses of 0, 0.01, 0.1, or 1 mg/kg for seven consecutive days. No statistically significant change in any region was observed at doses of 0.01 or 0.1 mg/kg.
Route of Administration:
Intramuscular
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:22:32 GMT 2023
by
admin
on
Fri Dec 15 16:22:32 GMT 2023
|
| Record UNII |
2GB92V6H2O
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
208186-69-0
Created by
admin on Fri Dec 15 16:22:33 GMT 2023 , Edited by admin on Fri Dec 15 16:22:33 GMT 2023
|
PRIMARY | |||
|
2GB92V6H2O
Created by
admin on Fri Dec 15 16:22:33 GMT 2023 , Edited by admin on Fri Dec 15 16:22:33 GMT 2023
|
PRIMARY | |||
|
6918345
Created by
admin on Fri Dec 15 16:22:33 GMT 2023 , Edited by admin on Fri Dec 15 16:22:33 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
ANHYDROUS->SOLVATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |